"And let's not forget that these great results were from Phase 1 SAFETY trials, they were not even optimized as to dosage size and schedule"
Exactly.
Efficacy was not a primary endpoint, and post hoc cherry picking of data from Phase I studies has led to many Phase II failures among anti-cancer candidates.
Today's PR was a disgrace whether you look at from a GCP or a CSR perspective.
No wonder Mr. Market is selling (at least I assume it's Mr. Market, but maybe insiders know soemthing too).
the K trial at DF was a phase 1b trial which also was designed to test for efficacy besides safety. we had efficacy published at the 2012 R&R conference. Dr menon was calling for p21 PCR tests in feb 2012 based on the results he was seen at that time.
we have come a long way with increasingly better results as the dosage is increased. a pancreatic cancer beneficial result for one.
that is all spectacular in itself. the added bonus is no DNA damage a comparatively minor side effects.
Market Data 
Markets 
AI
